Oncogene Cancer Research retweetledi
Oncogene Cancer Research
3.4K posts
Oncogene Cancer Research
@OncogeneCancer
🔬 Research. Empowerment. Advocacy. Patients & families improving #LCSM outcomes via education, support & cutting-edge research
London, England Katılım Mayıs 2023
1K Takip Edilen983 Takipçiler
Oncogene Cancer Research retweetledi
Explaining a cancer diagnosis to your children is one of the hardest things. Jessie, diagnosed with stage 4 EGFR lung cancer, shares how she explained it to her three kids. Episode with Jessie on our YouTube channel.
Thank you to @JNJNews
English
Oncogene Cancer Research retweetledi
Cancer isn’t a parasite; it’s our own cells that have lost their "off" switch. Using an antiparasitic won't fix a "transformed" cell. 🧬
Support ➡️ Giving.CU.EDU/CrackingCancer
youtu.be/zJhK6J1cZ3k
YouTube
English
Oncogene Cancer Research retweetledi
Upcoming Webinar: Living Well with ALK+ Lung Cancer
Join The Patient Story on Tuesday, May 19 for an important conversation featuring Dr. Ross Camidge and ALK Positive Board member Nancee Pronsati.
Register now: tinyurl.com/8pnek2mz
#ALKPositive #LungCancer #ALK #NSCLC
English
Oncogene Cancer Research retweetledi
Have to say #ASCO26 is going to be an amazing update into all things RET for lung and other cancers. Do make sure you checkout these sessions /posters to be fully up to speed. You won’t regRET it… @ASCO @VivekSubbiah
English
Oncogene Cancer Research retweetledi
A team led by Dr. John Heymach has been selected to receive the LCRF | Boehringer Ingelheim Team Science Award on Innovative Therapeutic Strategies to Understand and Treat Lung Cancers Harboring HER2 Mutations – a $1.5M award. LCRF.org/2025her2teamsc…
#LungCancer #LungCancerResearch
English
Oncogene Cancer Research retweetledi
After the former YouTube CEO, Susan Wojcicki, died of lung cancer at 56, her husband and sisters are continuing her mission to improve how the disease is detected and treated. @ReeveWill has the story.
English
Oncogene Cancer Research retweetledi
Upcoming webinar: Blossom Hill SOLARA Trial & 2026 ACCR updates
register here: us06web.zoom.us/meeting/regist…
English
Oncogene Cancer Research retweetledi
⭐️Everything in this post is directly relevant to #lungcancer as well. #SATEEN answers the value of using sequential ADCs with a topoisomerase payload.
⚠️The answer.. There minimal to no value in sequencing ADCs with the same payload.
@lcsmchat @OncoAlert @OncogeneCancer @Lung_Cancers @LungCancerEu @LungCancerRx @MedwatchKate
Mali Barbi, MD MSc | Breast & Gyn Oncologist@DrBarbiOnc
Two prospective phase II trials at #ESMOBC26 just settled something the field has been debating retrospectively. #SATEEN (LBA4): #saci+ #trastuzumab after prior T-DXd in HER2+ MBC. ORR 3.7%. One response in 27 patients. Median PFS 2.3 months. Stopped for futility. #HER3_DXd: ORR 39% in ADC-naive HR+/HER2- disease. Prior TOPO1 ADC exposure wiped that out across every subtype. Different antibody targets. Same collapse. Because resistance here is payload-driven, not antigen-driven. SN-38 and DXd are different molecules but the same mechanism. Abelman et al. (Clin Cancer Res 2025) showed acquired TOP1 mutations in 12.9% of patients at ADC progression median duration on the second TOPO1 ADC: 52 days versus 455 on the first. >>Post-ADC trial design has to start from the payload up, not the target down. #ESMOBC26 #BCsm
English
Oncogene Cancer Research retweetledi
Such careful communication matters enormously for patients, particularly for those with young-onset and oncogene-driven disease. Worth a watch for patients, family, and clinicians navigating the sea of misinformation. @YoungLungCancer @EGFRResisters @ALKPositiveinc @IASLC
English
Oncogene Cancer Research retweetledi
Crucial reality check from @lungoncdoc: Association ≠ causation‼️ Headlines linking healthy diet/pesticides to young onset lung cancer wildly overstate limited observations without proper controls, confounder adjustment, or any assessment of causality.
instagram.com/reel/DYATLHSvr…
English
Oncogene Cancer Research retweetledi
🎉EXCITED to have participated in and share our work on modelling TKI resistance in #RET #NSCLC using novel murine models.
⭐️This work was led by my brilliant colleagues Drs. Trista Hinz, Lynn Heasley & Rafe Nemenoff, @CUCancerCenter!
👇🏽SEE BELOW for details 🧵(1/9)
English
Together we can move research faster
Proud to support this webinar on May 14 at 13.30ET from @lcrf_org & Susan Wojcicki Foundation on heritable genetics, genomics & lung cancer research w Drs @PatelOncology @ipreeshagul @JFreemanDaily & @ALKPositiveinc
👉lnkd.in/gFcBUffA
English
Oncogene Cancer Research retweetledi
As #HopeSummit closes, we’re reflecting on a weekend full of connection & hope 🤍
From Dr @DRCamidge’s keynote to the ALK breakout with Dr. David Gerber, it was powerful to come together—patients, care partners, advocates, clinicians.
We leave energised to keep sharing hope 💙
English
Oncogene Cancer Research retweetledi
YLCI Booth at @LUNGevity HOPE Summit… Thank you to Leah for holding down the fort! Come find us and say hi if you’re there 👋🤍
English
Sarah was training for marathon #7 when a cough changed everything. It was stage 4, EGFR ex 21 #lungcancer
But it hasn't changed her determination
On 3 May, Sarah & 10 friends take on @UltraChallenges - not just for the finish line, but for time
👉oncogeneresearch.org/sarahs-ultrama… #LCSM
English
As a #lungcancer community, we see the impact of myths every day - delaying diagnosis, shaping who gets screened, influencing research funding.
This @CNN piece challenges 7 of the most persistent misconceptions & highlights where science is moving.
edition.cnn.com/2026/04/29/hea… #LCSM
English
There is something powerful about the @LondonMarathon. The theme music makes us nostalgic, the costumes make us smile and the stories make us emotional.
Especially gratetul to Mandy supporting our continued work at @ICR_London.
Read more👇
oncogeneresearch.org/icr-festival-t…
#LCSM
English
Oncogene Cancer Research retweetledi
Jeff’s story shows what’s possible when clinicians, researchers & companies work together to find a path forward for an individual patient.
Let’s hope zidesamtinib can become an option when neladalkib isn’t tolerated due to liver tox while we push for solutions for all.
ALK Positive@ALKPositiveinc
After discontinuing the NVL-655 trial due to liver toxicity, ALK-positive patient and ALK Positive board member, Jeff Sturm, accessed the investigational drug zidesamtinib through a single-patient IND. Read his experience here: alkpositive.org/blog/patient-p… #LearnAboutALKPositive
English
Oncogene Cancer Research retweetledi
For decades, KRAS was considered "undruggable." Here's why that changed & what it means for lung cancer patients
Full 3 part series w/ Dr. @FawziAbuRous on YouTube: youtube.com/playlist?list=…
Thank you to @RevMedicines for sponsoring
YLCI retains editorial control over content
English